Table 1.
Summarised socio‐demographic variables (gender, age, admission to ICU), number of comorbidities, and COVID‐19 symptoms
| Sex | Age (years old) | Comorbidities | Time from start symptoms (Days a | COVID‐19 symptoms | ICU (OTI) Time OTI | Complications | Death (days) Cause of death | Treatment b | Antifungal therapy | Isolate | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | Male | 75 | Sleep apnoea syndrome, Basal‐cell carcinoma, Diabetes mellitus type 2, arterial hypertension, dyslipidemia, COPD | 20 | Dyspnoea, cough, and fever | YES (YES) 5 days | Pneumothorax, sepsis, atrial fibrillation, severe myopathy and acute renal failure | YES (25) Sepsis | Tocilizumab (600 mg) Methylprednisolone (40 mg/day) Interferon β‐1b | No treatment | A. fumigatus |
| Case 2 | Male | 42 | Morbid obesity | 12 | Cough, sputum, dyspnoea, and fever | YES (YES) 11 days | Thoracic bleeding, sepsis, severe myopathy, acute renal failure, multiorgan failure and atrial fibrillation | YES (23) Sepsis | Methylprednisolone (40 mg/day) | Itraconazole (IV): 200 mg Q12H × 48 h. Subsequent, daily starting day 3 200 mg Q24H | A. fumigatus |
| Case 3 | Female | 60 | Morbid obesity, peptic ulcer, extrinsic allergic alveolitis | 10 | Fever, malaise, diarrhoea and headache | YES (YES) 10 days | Sepsis, atrial fibrillation, severe myopathy and acute renal failure | YES (20) | Lopinavir/Ritonavir (400 mg/100 mg) | No treatment | A. niger |
| Case 4 | Female | 58 | Sleep apnoea syndrome, and arterial hypertension | 15 | Fever, malaise, cough and dyspnoea | YES (YES) 7 days | Acute renal failure, and severe myopathy | NO | Tocilizumab (1.600 mg) Methylprednisolone (120 mg daily ‐ for 3 days) | Itraconazole (IV): 200 mg Q12H × 48 h. Subsequent, daily starting day 3 200 mg Q24H until the ninth day PO: 200 mg Q24H for 60 days | A. flavus |
| Case 5 | Male | 70 | Diabetes mellitus type 2, and arterial hypertension | 11 | Fever, malaise, cough and dyspnoea | NO (NO) | Atrial fibrillation, and pulmonary embolism | YES (42) Organ failure | Tocilizumab (600 mg) Methylprednisolone (120 mg daily ‐ for 3 days) | Itraconazole IV: 200 mg Q12H × 48 h. Subsequent, daily starting day 3 200 mg Q24H | A. fumigatus |
| Case 6 | Male | 55 | Diabetes mellitus type 2, and arterial hypertension | 10 | Dyspnoea, cough, and fever | YES (YES) 5 days | Acute renal failure | NO (28) | Tocilizumab (600 mg) Methylprednisolone (120 mg daily ‐ for 3 days) | Amphotericin B deoxycholate (ABD) (IV) 5 mg / kg / day | A. niger |
| Case 7 | Male | 57 | No known comorbidity | 12 | Dyspnoea, cough, and fever | YES (YES) 18 days | Pneumothorax, thoracic bleeding, pulmonary infarction, sepsis, acute renal failure, severe myopathy and Broncho‐pulmonary fistula | YES (30) Sepsis | Tocilizumab (600 mg) Methylprednisolone (250 mg daily ‐ for 3 days) | Itraconazole (IV): 200 mg Q24H until the ninth day PO: 200 mg Q24H for 60 days | A. flavus |
Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; COVID‐19, Coronavirus Disease 2019; ICU, Intensive Care Unit; IV (Intravenous), administration within or into a vein or veins; OTI, Orotracheal intubation; PO (Oral), Administration to or by way of the mouth.
a
‘Time from start symptoms’ refers to the time from the beginning of the symptoms to hospital admission.
b
All patients received Azithromycin 500 mg for 3 days, Hydroxychloroquine sulphate 5 mg/kg (310 mg base) for 7 days and third‐generation cephalosporins for 7 days.